Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020139956 - BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITONS AND METHODS THEREOF, FOR TREATMENT OF CANCER AND OTHER DISEASES

Publication Number WO/2020/139956
Publication Date 02.07.2020
International Application No. PCT/US2019/068591
International Filing Date 26.12.2019
IPC
C07K 16/18 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A61P 35/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A01K 2207/12
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2207Modified animals
12Animals modified by administration of exogenous cells
A01K 2227/105
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2227Animals characterised by species
10Mammal
105Murine
A01K 2267/0331
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
KANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
2267Animals characterised by purpose
03Animal model, e.g. for test or diseases
0331Animal model for proliferative diseases
C07K 16/2827
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2803against the immunoglobulin superfamily
2827against B7 molecules, e.g. CD80, CD86
C07K 2317/51
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
51Complete heavy chain or Fd fragment, i.e. VH + CH1
C07K 2317/515
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
50characterized by immunoglobulin fragments
515Complete light chain, i.e. VL + CL
Applicants
  • SPARX THERAPEUTICS INC. [US]/[US]
Inventors
  • ZHU, Guidong
  • YE, Jingdong
  • QIN, Jingdong
  • MA, Jichun
Agents
  • CILELLA, Magdalena, O.
Priority Data
62/786,01228.12.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BINDING MOLECULES SPECIFIC FOR CLAUDIN 18.2, COMPOSITONS AND METHODS THEREOF, FOR TREATMENT OF CANCER AND OTHER DISEASES
(FR) MOLÉCULES DE LIAISON SPÉCIFIQUES DE LA CLAUDINE 18.2, COMPOSITIONS ET PROCÉDÉS ASSOCIÉS, POUR LE TRAITEMENT DU CANCER ET D'AUTRES MALADIES
Abstract
(EN)
Compositions and methods of making isolated binding molecules (e.g. an antibodies) or antigen-binding fragment thereof useful as therapeutics for treating and/or preventing diseases associated with cells expressing claudinl8.2, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder are described. Also, described are pharmaceutical formulations comprising the described compositions for the treatment of diseases either as single agent (e.g., naked antibodies) or as adjuvant therapy with other antigen-binding anti cancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies), and/or by combination therapies where the anti-claudinl8.2 antibodies are administered before, after, or concurrently with chemotherapy.
(FR)
La présente invention concerne des compositions et des méthodes de fabrication de molécules de liaison isolées (par exemple, des anticorps) ou un fragment de liaison à un antigène correspondant utiles en tant que produits thérapeutiques pour le traitement et/ou la prévention de maladies associées à des cellules exprimant la claudine 18.2, dont des maladies liées à une tumeur telles que le cancer de l'estomac, le cancer de l'œsophage, le cancer du pancréas, le cancer du poumon, le cancer des ovaires, le cancer du côlon, le cancer du foie, le cancer de la tête et du cou, et le cancer de la vésicule biliaire. L'invention concerne également des formulations pharmaceutiques comprenant les compositions décrites pour le traitement de maladies soit en tant qu'agent unique (par exemple, des anticorps nus) soit en tant que thérapie adjuvante avec d'autres agents anticancéreux de liaison à l'antigène tels que des inhibiteurs de points de contrôle immunitaires (par exemple, des anticorps monoclonaux anti-CTLA-4 et anti-PD-1/PD-L1), et/ou par des polythérapies dans lesquelles les anticorps anti-claudine 18.2 sont administrés avant, après, ou simultanément à une chimiothérapie.
Also published as
Latest bibliographic data on file with the International Bureau